Modality
Bispecific Ab
MOA
VEGFi
Target
CD123
Pathway
PD-1/PD-L1
BCC
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
~Feb 2017
→ ~May 2018
Phase 3
Aug 2018
→ Apr 2025
Phase 3Current
NCT08698286
1,530 pts·BCC
2021-04→2025-04·Completed
NCT06276105
437 pts·BCC
2018-08→TBD·Recruiting
1,967 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-04-1312mo agoPh3 Readout· BCC
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P3
Recruit…
P3
Complet…
Catalysts
Ph3 Readout
2025-04-13 · 12mo ago
BCC
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08698286 | Phase 3 | BCC | Completed | 1530 | DAS28 |
| NCT06276105 | Phase 3 | BCC | Recruiting | 437 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| REG-7737 | Regeneron | Preclinical | CD123 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Gozeosocimab | Illumina | Phase 2 | BCMA | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| RLA-8772 | Relay Therapeutics | Phase 2 | MALT1 |